The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Increase Is Anticipated For The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Over The 2026–2030 Period?
The market size for nucleic acid and gene therapies in neuromuscular disorders has shown strong growth in recent years. It is anticipated to increase from $7.5 billion in 2025 to $8.22 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.7%. Historically, this growth can be attributed to elements such as limited therapeutic options for neuromuscular disorders, low awareness regarding gene therapies, the high expense of developing gene therapies, a scarcity of specialized treatment centers, and slow regulatory approval processes.
The nucleic acid and gene therapies in neuromuscular disorders market is anticipated to observe significant growth over the next few years. It is projected to expand to $11.76 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.4%. This growth in the forecast period can be attributed to advancements in adeno-associated virus and postnatal gene therapies, increased research and development investments in neuromuscular disorders (NMDs), a rising number of hospitals and specialty clinics offering gene therapies, the growing prevalence of neuromuscular disorders, and increasing patient awareness and advocacy initiatives. Major trends for the forecast period include the rising adoption of gene therapy techniques, the increasing development of nucleic acid therapeutics, a growing focus on rare neuromuscular disorders, rising investment in personalized medicine approaches, and the increasing integration of advanced diagnostic and monitoring tools.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21233&type=smp
What Underlying Factors Are Accelerating The Growth Of The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
The escalating occurrence of genetic conditions is projected to drive the expansion of the nucleic acid and gene therapies in neuromuscular disorders market in the future. These disorders are illnesses arising from irregularities in a person’s DNA, which can be inherited or develop from mutations. The rise in genetic disorders stems from elements like genetic alterations, environmental factors, shifts in lifestyle, and enhanced diagnostic tools. Nucleic acid and gene therapies address genetic disorders by rectifying or substituting faulty genes within neuromuscular conditions, aiming to reinstate typical functionality. As an illustration, in May 2024, data from Cure SMA, a US-based non-profit organization, indicated that around 9,000 to 9,500 people in the United States are currently affected by Spinal Muscular Atrophy (SMA). Of this total, 37% suffer from Type 2 SMA, with the condition’s estimated occurrence being 1 in 15,000 births. Consequently, the growing frequency of genetic disorders is propelling the advancement of the nucleic acid and gene therapies in neuromuscular disorders market.
How Is The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Segmented Across Key Categories?
The nucleic acid and gene therapies in neuromuscular disorders market covered in this report is segmented –
1) By Disorder: Motor Neuron Diseases, Neuropathies, Neuromuscular Junction Disorders, Myopathies Including Muscular Dystrophies
2) By Therapy: Adeno-Associated Viruses Gene Therapy, Postnatal Gene Therapy
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgery Centers
Subsegments:
1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS)
2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT), Hereditary Sensory and Autonomic Neuropathy (HSAN), Peripheral Neuropathies
3) By Neuromuscular Junction Disorders: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome (LEMS)
4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD)
Which Upcoming Trends Are Expected To Influence The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
Leading companies within the nucleic acid and gene therapies in neuromuscular disorders market are dedicated to creating ground-breaking treatments, including gene therapy, to tackle the fundamental causes of genetic neuromuscular conditions via precise gene correction or substitution. Gene therapy involves managing diseases by inserting, modifying, or mending genetic material inside a patient’s cells to rectify or substitute faulty genes. An example of this is the approval granted in June 2023 by the U.S. Food and Drug Administration to Sarepta Therapeutics Inc., a US-based biotechnology company, for Elevidys. This marked the initial gene therapy designed for Duchenne Muscular Dystrophy, specifically targeting ambulatory pediatric patients aged 4 to 5 years. This treatment is given as a single intravenous infusion, streamlining the therapeutic procedure when contrasted with other treatments that might necessitate continuous infusions. ELEVIDYS introduces a gene responsible for producing micro-dystrophin, a shorter variant of dystrophin crucial for proper muscle function. This pioneering method tackles the foundational genetic flaw by allowing muscle cells to generate a working form of the dystrophin protein, potentially arresting or reversing the disease’s advancement.
Who Are The Dominant Players Shaping The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Landscape?
Major companies operating in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Sanofi S.A, Novartis AG, Biogen Inc, BioMarin Pharmaceuticals Inc, Sarepta Therapeutics Inc, Ionis Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Regenxbio Inc, UniQure N.V, Généthon S.A, Axovant Gene Therapies Inc, PTC Therapeutics Inc, Wave Life Sciences Ltd, CRISPR Therapeutics AG, Editas Medicine Inc, Helixmith Co Ltd, MeiraGTx Ltd, Cure Rare Disease, Beam Therapeutics Inc, Intellia Therapeutics Inc, Prime Medicine Inc, Arcturus Therapeutics Holdings Inc, Takeda Pharmaceutical Company Ltd.
Read the full nucleic acid and gene therapies in neuromuscular disorders market report here:
Which Region Is Projected To Dominate The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market During The Forecast Period?
North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2025. The regions covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=21233&type=smp
Browse Through More Reports Similar to the Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market 2026, By The Business Research Company
Prostate Cancer Nuclear Medicine Diagnostics Global Market Report
Nuclear Medicine Global Market Report
https://www.thebusinessresearchcompany.com/report/nuclear-medicine-global-market-report
Hereditary Cancer Testing Global Market Report
https://www.thebusinessresearchcompany.com/report/hereditary-cancer-testing-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model